Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer. The oversubscribed rights issue (securing SEK113m in gross proceeds) will remove the principal financing overhang, and any future financing needs are likely to be non-dilutive, underpinned by target cash flow break-even following the successful execution of product launches. We believe the combination of resolved financing, advancing commercial readiness and two imminent binary catalysts represents a potentially de-risking moment for the stock.
LÄS MER
